Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Por Milana Bergamino, Antonio J. Rullan, Maria Saigí, Inmaculada Peiró, Eduard Montanya, Ramón Palmero, José Carlos Ruffinelli, Arturo Navarro, María Dolores Arnaiz, Isabel Brao, Samantha Aso, Susana Padrones, Felipe Cardenal, Ernest Nadal
Publicado em 2019-02-01